Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report.
HSCT
SARS-CoV-2 infection
antigen-specific response
antivirals
dual antiviral therapy
immunocompromised
prolonged infection
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2024
2024
Historique:
received:
07
09
2023
accepted:
29
01
2024
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
28
2
2024
Statut:
epublish
Résumé
Here we describe the case of a 51 years old Italian woman with acute lymphoblastic leukemia who underwent to hematopoietic stem cell transplantation (HSCT) during SARS-COV-2 infection. She presented a prolonged COVID-19 successfully treated with dual anti SARS-COV-2 antiviral plus monoclonal antibody therapy.
Identifiants
pubmed: 38414746
doi: 10.3389/fonc.2024.1290614
pmc: PMC10896944
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1290614Informations de copyright
Copyright © 2024 Vita, D’Abramo, Coppola, Farroni, Iori, Faraglia, Sette, Grifoni, Lindestam Arlehamn, Bibas, Goletti and Nicastri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.